Gene · 6375
Papers2,385
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,385
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. | Nat Immunol | 2023 | 37081150 | PubTator, text mining | PubMed |
| MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors. | Korean J Physiol Pharmacol | 2023 | 37078298 | PubTator, text mining | PubMed |
| Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification. | J Proteome Res | 2023 | 37071664 | PubTator, text mining | PubMed |
| Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity. | Front Immunol | 2023 | 37063898 | PubTator, text mining | PubMed |
| Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma. | Aging (Albany NY) | 2023 | 37059591 | PubTator, text mining | PubMed |
| Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis. | Hepatol Commun | 2023 | 37058121 | PubTator, text mining | PubMed |
| Identification of immune cell infiltration landscape for predicting prognosis of colorectal cancer. | Gastroenterol Rep (Oxf) | 2023 | 37056281 | PubTator, text mining | PubMed |
| POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2023 | 37047824 | PubTator, text mining | PubMed |
| The Role of Cytokines in Cholesterol Accumulation in Cells and Atherosclerosis Progression. | Int J Mol Sci | 2023 | 37047399 | PubTator, text mining | PubMed |
| Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. | Cancer Cell | 2023 | 37037616 | PubTator, text mining | PubMed |
| Targeting GPC3high cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer. | Ann Med | 2023 | 37036308 | PubTator, text mining | PubMed |
| Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions. | Cancer Discov | 2023 | 37021392 | PubTator, text mining | PubMed |
| Robust fusion for skin lesion segmentation of dermoscopic images. | Front Bioeng Biotechnol | 2023 | 37020509 | PubTator, text mining | PubMed |
| A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma. | Front Immunol | 2023 | 37006314 | PubTator, text mining | PubMed |
| Tumor microenvironment signaling and therapeutics in cancer progression. | Cancer Commun (Lond) | 2023 | 37005490 | PubTator, text mining | PubMed |
| Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. | Cancer Cell | 2023 | 37001526 | PubTator, text mining | PubMed |
| Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases. | Inflammopharmacology | 2023 | 36997729 | PubTator, text mining | PubMed |
| The unfolding story of dying tumor cells during cancer treatment. | Front Immunol | 2023 | 36993986 | PubTator, text mining | PubMed |
| Clonal associations of lymphocyte subsets and functional states revealed by single cell antigen receptor profiling of T and B cells in rheumatoid arthritis synovium. | bioRxiv | 2023 | 36993527 | PubTator, text mining | PubMed |
| Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. | Sci Rep | 2023 | 36991099 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6375/papers?page=25